ESC Premium Access

Opening remarks - A closer look at glucose lowering agents CV safety results and current heart failure guidelines.

Presentation

About the speaker

Doctor Anselm Kai Gitt

Klinikum Ludwigshafen, Ludwigshafen (Germany)
12 presentations
0 follower

3 more presentations in this session

Latest insights from the TECOS Trial: clarifying the role for dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of cardiovascular patients with type 2 diabetes and heart failure.

Speaker: Doctor E. Peterson (Dallas, US)

Thumbnail

Roundtable discussion: what can we learn from current guidelines – Do they accurately reflect current knowledge and what can we expect over time?

Speaker: Doctor E. Peterson (Dallas, US) Professor L. Ryden (Stockholm, SE)

Thumbnail

Closing remarks - A closer look at glucose lowering agents cardiovascular safety results and current heart failure guidelines.

Speaker: Doctor A. Gitt (Ludwigshafen, DE)

Thumbnail

Access the full session

A closer look at glucose lowering agents cardiovascular safety results and current heart failure guidelines

Speakers: Doctor A. Gitt, Doctor E. Peterson, Doctor E. Peterson, Professor L. Ryden, Doctor A. Gitt
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk